

type of report	Current report
number	24/2013
company	PHARMENA

Formulation development of 1-MNA dietary supplement

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13th April 2012) and communication on entering into agreement on 1-MNA dietary supplement formulation development (published in current report no. 07/2013 of 11th February 2013), the Management Board of Pharmena S.A. informs that on 16th May 2013, conceptual works (commissioned to Master Pharm Polska Sp. z o.o.) over the development of 1-MNA dietary supplement formulation were finalised. The Company's next step is to produce a pilot batch of the product and undertake its analytical research.

Having concluded the above described works and successfully finalised the registration processes of 1-MNA dietary supplement as new foodstuff within the European procedure, the company Pharmena S.A. will place the product on EU markets.

Dietary supplement 1-MNA is an innovative product with a capacity to influence the risk biomarkers of cardiovascular diseases and to stimulate the endogenous (natural) production of prostacyclin. Low levels of prostacyclin in human organism increase the risk of atherosclerosis. Studies have shown that the concentration of endogenous 1-MNA in human organism decreases with age. 1-MNA dietary supplement can complement 1-MNA deficiency in the organism and therefore stimulate the production of prostacyclin which reduces the risk of atherosclerosis development.

Master Pharm Polska Sp. z o.o. is a Polish leader in developing and contract manufacturing of dietary supplements, foods for particular nutritional uses, cosmetics, medical products.

The information is made public due to the fact that introduction of innovative dietary supplement containing 1-MNA on the market may have a significant influence on the Company's revenue in the next few years.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board